Erin Harris: CRISPR Gene Therapy in Children
Erin Harris, Chief Editor and Host of Cell and Gene The Podcast, shared a post on LinkedIn:
“Back in June, new research published in The New England Journal of Medicine reported encouraging results for exa-cel, a CRISPR-based therapy, in children ages 5 to 11 with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
And so I wanted to speak with Dr. Haydar Frangoul, medical director of the Pediatric Stem Cell Transplant Program at HCA Healthcare’s TriStar Centennial Children’s Hospital in Nashville, because this research raises important questions beyond the initial results.
There’s a lot to consider as gene editing moves into younger patient populations. Dr. Frangoul and I covered a lot of ground, here’s Part 1 of our conversation.
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 10:48Tareq Abadl: Why the Kell Blood Group System Matters
-
Nov 16, 2026, 10:40TIF in China – Advancing Regional Cooperation in Thalassaemia Prevention and Care
-
Nov 16, 2026, 10:40Dhargam Aljebouri: A Milestone for Transfusion Medicine in Iraq
-
Nov 16, 2026, 10:35Arisha Patel: Why a Normal Blood Count Can Miss Iron Deficiency
-
Nov 16, 2026, 10:29Maxime Dely: The Needle Behind Every Donation
-
Nov 16, 2026, 10:29Marilena Vrana: Building a Resilient Plasma Ecosystem in Europe
-
Nov 16, 2026, 10:24Hichem Selatna: Advancing Hematology Laboratory Automation
-
Nov 16, 2026, 10:19Beverley Hunt: PE Knows No Age – Isaac’s Story
-
Nov 16, 2026, 10:08Abdul Mannan: When Normal Blood Counts Hide Iron Deficiency